Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
| العنوان: | Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 |
|---|---|
| المؤلفون: | Gregory D. Huhn, Dipak R. Patel, Bharat Mocherla, Daniel Skovronsky, Kenneth L. Custer, Paul Klekotka, Imad Shawa, Andrew E. Schade, Janelle Sabo, Nicole L. Kallewaard, Michael Durante, Andrew C. Adams, Timothy R. Holzer, Ajay Nirula, Joseph Boscia, Masoud Azizad, Jose Cardona, Princy Kumar, Chad Crystal, Lei Shen, Peter Chen, Russell Perry, Corey Hebert, Richard E. Higgs, Robert L. Gottlieb, Matan C. Dabora, Philip J. Ebert, Jacob Van Naarden, Gerard J. Oakley, Jason Morris, Michael Dougan, Awawu Igbinadolor, Barry Heller |
| المصدر: | The New England Journal of Medicine |
| بيانات النشر: | Massachusetts Medical Society, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, 2019-20 coronavirus outbreak, Adolescent, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized, Gastroenterology, law.invention, Young Adult, Pharmacotherapy, Double-Blind Method, Randomized controlled trial, Risk Factors, law, Immunity, Internal medicine, medicine, Humans, Young adult, Child, Infusions, Intravenous, Aged, SARS-CoV-2, business.industry, Patient Acuity, COVID-19, General Medicine, Middle Aged, Viral Load, COVID-19 Drug Treatment, Hospitalization, Increased risk, Original Article, Drug Therapy, Combination, Female, business |
| الوصف: | Background Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive immunity and may limit disease progression and complications. Methods In this phase 3 trial, we randomly assigned, in a 1:1 ratio, a cohort of ambulatory patients with mild or moderate Covid-19 who were at high risk for progression to severe disease to receive a single intravenous infusion of either a neutralizing monoclonal-antibody combination agent (2800 mg of bamlanivimab and 2800 mg of etesevimab, administered together) or placebo within 3 days after a laboratory diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The primary outcome was the overall clinical status of the patients, defined as Covid-19–related hospitalization or death from any cause by day 29. Results A total of 1035 patients underwent randomization and received an infusion of bamlanivimab–etesevimab or placebo. The mean (±SD) age of the patients was 53.8±16.8 years, and 52.0% were adolescent girls or women. By day 29, a total of 11 of 518 patients (2.1%) in the bamlanivimab–etesevimab group had a Covid-19–related hospitalization or death from any cause, as compared with 36 of 517 patients (7.0%) in the placebo group (absolute risk difference, −4.8 percentage points; 95% confidence interval [CI], −7.4 to −2.3; relative risk difference, 70%; P |
| تدمد: | 1533-4406 0028-4793 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::163d2b1d9fb708ea8c2b335a117a4a4b https://doi.org/10.1056/nejmoa2102685 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....163d2b1d9fb708ea8c2b335a117a4a4b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15334406 00284793 |
|---|